Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 8/20 | 0.63 |
| ▸ | LTA4H | P09960 | 3/20 | 0.58 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.58 |
| ▸ | MPO | P05164 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.52 |
| ▸ | MC5R | P33032 | 1/20 | 0.52 |
| ▸ | MC3R | P41968 | 1/20 | 0.52 |
| ▸ | MC1R | Q01726 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5947562 | 0.95 | HTR2A (0.68) | KMT2AHTR2ALTA4HPLA2G2APOLB | |
| SCHEMBL5947104 | 0.94 | HTR2A (0.67) | KMT2AHTR2ALTA4HPLA2G2APOLB | |
| SCHEMBL2534484 | 0.91 | HTR2A (0.71) | KMT2AHTR2ALTA4HPLA2G2AMPO | |
| SCHEMBL2536494 | 0.88 | HTR2A (0.82) | KMT2AHTR2ALTA4HPLA2G2AMAPT | |
| SCHEMBL5947571 | 0.88 | KMT2A (0.79) | KMT2AHTR2ALTA4HPLA2G2AMPO | |
| SCHEMBL5947953 | 0.87 | KMT2A (0.62) | KMT2AHTR2ALTA4HPLA2G2AMPO | |
| SCHEMBL5947200 | 0.87 | SNCA (0.64) | KMT2AHTR2ALTA4HPLA2G2AMPO | |
| SCHEMBL5947129 | 0.87 | KMT2A (0.62) | KMT2AHTR2ALTA4HPLA2G2AMPO | |
| SCHEMBL2541899 | 0.87 | KMT2A (0.62) | KMT2AHTR2ALTA4HPLA2G2AMPO | |
| SCHEMBL5947510 | 0.87 | HTR2A (0.63) | KMT2AHTR2ALTA4HPLA2G2AMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | CHEN ZHAOGEN | 2006-01-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | HTR6, HTR2C, HTR1B | KMT2A 1269/4885HTR2A 5/4885LTA4H 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.